December 10, 2025, Innovative Medical Device EnterprisesImpulse Dynamics Announcement Completed $1.58 billion in financing (approximately RMB11.2100 million), with the participation of multiple investment institutions such as Sands Capital and Braidwell, and continued investment from existing shareholders like Redmile, Perceptive Advisors, and Alger. The company stated that the funds from this round will be used to expand its heart failure (HF) treatment technology. CCM^®(Cardiac Contractility Modulation, CCM)The commercial scale, accelerate the progress of multiple ongoing clinical trials, and strengthen the research and development of next-generation implantable devices, including new systems that integrate CCM with ICD functions.

The timing of the financing is particularly important.This year, the United States Medicare (CMS) officially releasedNational Coverage Decision (NCD), will CCM^®Included in the reimbursement system,This has substantially improved its clinical accessibility in the United States and also created a policy foundation for a new round of commercial expansion and capital investment. For the field of heart failure treatment, which has long been limited by few treatment options and slow innovation, CCM^®With the breakthrough in the payment system, it is entering a clearer clinical promotion cycle.

# Company Introduction: A Device Innovation Enterprise Positioned to Address the Gap in Heart Failure Treatment

Impulse Dynamics is a medical device company focused on the treatment of moderate to severe heart failure, with its main products and R&D pipeline centered around Cardiac Contractility Modulation (CCM) TherapyExpand. Over the past few decades, innovations in heart failure treatment have mostly focused on medications (such as ARNI, SGLT2i) or device therapies for specific populations (such as CRT, ICD). However, a significant number of heart failure patients still fall into a clinical gap where they experience "insufficient improvement with drug therapy but do not meet the criteria for CRT."

Impulse Dynamics is targeting precisely this gap:Focusing on enhancing myocardial contractile efficiency, improving patient symptoms and quality of life without relying on altering heart rhythm or electrical conduction pathways.

The company's flagship product performs CCM.^®Implantable Device Optimizer^®Series, which has been applied in more than 12,000 patients worldwide and received regulatory approvals in multiple countries. The company is also building an expanding product pipeline, including next-generation integrated devices.CCM-D^® HF System, to meet the more complex needs of heart failure patients.

In recent years, with the company having accumulated over a hundred published papers, thousands of real-world data cases, and several ongoing large-scale clinical trials, CCM^®The evidence system for the efficacy of Impulse Dynamics continues to improve. As the US payment system opens up to this technology, Impulse Dynamics' path has transitioned from "evidence accumulation" to a "deployable disease management tool."

# Product Introduction: CCM^®The Capability Boundary of Technology and Equipment Systems

CCM^®Is the core technology of Impulse Dynamics, and its mechanism belongs to a unique class of electrophysiological modulation strategies:ThroughIn the heartAbsolute Refractory PeriodRelease Specific Electrical Impulses, enhancing the calcium ion handling capacity of cardiomyocytes, thereby improving contractile efficiency.

Unlike ICD or CRT, which improve pumping capacity by "changing the activation sequence or synchronizing ventricular movement," CCM^®It does not affect the heart rhythm or attempt to adjust the conduction pathway, but rather acts directly on the myocardial cells themselves, making their energy utilization more efficient and improving their mechanical performance with each contraction.

Clinical studies have shown that this mechanism can improve patients' exercise tolerance, 6-minute walking distance, NYHA heart function class, and quality of life (KCCQ score), with clear value particularly for patients who still have significant symptoms despite medical treatment.

CCM^®The typical beneficiaries include NYHA Class III heart failure patients, especially those with a left ventricular ejection fraction (LVEF) between 25–45% but without significant QRS prolongation. These patients usually do not meet the criteria for CRT (Cardiac Resynchronization Therapy) and generally show insufficient response to medication, representing a group that has long lacked effective device-based solutions in the heart failure treatment system.

Over the past decade, it was precisely this clinical need that drove the development of CCM.^®The continuous development of technology has made it a representative innovative approach to fill this treatment gap.

Optimizer^®Series: CCM Execution Platform

Optimizer^®Is currently one of the main commercial products in use,This is a type of implantable pulse generator,Responsible for delivering modulated pulses to the heart within a specific time window and identifying rhythms and adjusting pulse parameters through built-in algorithms.Enables the treatment process to have a high degree of personalization and automation. As a long-term implantable system, it also has energy management and remote follow-up capabilities to meet the needs of heart failure patients. Optimizer^®It has been promoted in multiple markets, including Europe and the United States, and is gradually forming a distribution network covering major tertiary hospitals and heart failure specialty centers.

Next Generation Product: CCM-D^® HF System

# Conclusion

Impulse Dynamics' current round of financing occurred almost simultaneously with CMS' national coverage decision, and its industrial significance goes far beyond the capital level.

For heart failure, one of the most burdensome chronic diseases globally, new device-based treatment pathways have been scarce for a long time, while CCM^®'s growth provides a noteworthy signal:

• Technical mechanisms can fill the gaps in the existing treatment system.

• The clinical evidence system has reached a scalable condition.

• The openness of the payment system means true accessibility.

• The Next Generation Product Pipeline is Building Combined Management Capabilities

Heart failure treatment is gradually moving from the "drug + individual device" model towards a multimodal system characterized by modulation technology, integrated devices, and long-term management.
Impulse Dynamics is positioned precisely at the midpoint of this structural change.

With the injection of funds, the advancement of trials, and the liberalization of payment methods, the CCM market is expected to grow significantly in the coming years.^®Whether it can become a part of the standard system for heart failure management will be the most worthwhile direction to continuously observe in this field.